Zomedica's shares have lost around -28% of their value since the company announced the first sale of its Truforma system on March 16.
Truforma is a diagnostic platform for dogs and cats, and is Zomedica's first commercial product. On Nov. 13, Zomedica first announced its plans to commercialize Truforma leading to investors driving the company's stock price by +2,600%! Following the massive rally, many investors apparently decided to take some of their gains off the table on Zomedica's first sale.
Zomedica's announcement of its first sale probably made investors wary of the risks of investing in an early-stage growth company, and therefore they decided to take some of their profits from the stock.
ZOMDF saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 19, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on October 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ZOMDF as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
ZOMDF moved below its 50-day moving average on October 14, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZOMDF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ZOMDF entered a downward trend on October 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for ZOMDF's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZOMDF advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .
ZOMDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.469) is normal, around the industry mean (61.538). P/E Ratio (0.000) is within average values for comparable stocks, (37.887). ZOMDF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.694). ZOMDF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.019). P/S Ratio (2.073) is also within normal values, averaging (80.505).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZOMDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZOMDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company that develops medication for animals
Industry MedicalNursingServices